Wedbush Issues Pessimistic Outlook for PRAX Earnings

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) – Equities research analysts at Wedbush dropped their Q3 2025 earnings per share (EPS) estimates for Praxis Precision Medicines in a research note issued on Monday, October 20th. Wedbush analyst L. Chico now expects that the company will earn ($3.27) per share for the quarter, down from their previous estimate of ($3.23). Wedbush currently has a “Underperform” rating and a $73.00 target price on the stock. The consensus estimate for Praxis Precision Medicines’ current full-year earnings is ($10.22) per share. Wedbush also issued estimates for Praxis Precision Medicines’ Q4 2025 earnings at ($3.27) EPS, FY2025 earnings at ($13.14) EPS, Q1 2026 earnings at ($3.10) EPS, Q2 2026 earnings at ($3.21) EPS, Q3 2026 earnings at ($3.45) EPS, Q4 2026 earnings at ($3.60) EPS, FY2026 earnings at ($13.36) EPS, FY2027 earnings at ($14.43) EPS, FY2028 earnings at ($10.41) EPS and FY2029 earnings at ($5.15) EPS.

Praxis Precision Medicines (NASDAQ:PRAX) last posted its quarterly earnings data on Monday, August 4th. The company reported ($3.31) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.40) by $0.09.

Several other research analysts have also recently weighed in on the company. Lifesci Capital upgraded Praxis Precision Medicines to a “strong-buy” rating in a report on Wednesday, September 3rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Praxis Precision Medicines in a report on Wednesday, October 8th. Needham & Company LLC upped their price objective on shares of Praxis Precision Medicines from $80.00 to $250.00 and gave the company a “buy” rating in a research note on Thursday, October 16th. HC Wainwright raised their price objective on shares of Praxis Precision Medicines from $115.00 to $232.00 and gave the company a “buy” rating in a research report on Thursday, October 16th. Finally, Oppenheimer raised their price objective on shares of Praxis Precision Medicines from $97.00 to $115.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 8th. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $222.36.

Praxis Precision Medicines Trading Down 2.9%

NASDAQ:PRAX opened at $184.43 on Wednesday. Praxis Precision Medicines has a 12 month low of $26.70 and a 12 month high of $205.89. The stock has a 50 day moving average of $60.95 and a two-hundred day moving average of $48.86. The firm has a market cap of $3.90 billion, a P/E ratio of -15.01 and a beta of 2.62.

Institutional Investors Weigh In On Praxis Precision Medicines

Hedge funds and other institutional investors have recently modified their holdings of the stock. Woodline Partners LP grew its position in shares of Praxis Precision Medicines by 1,666.5% during the 1st quarter. Woodline Partners LP now owns 175,727 shares of the company’s stock valued at $6,655,000 after buying an additional 165,779 shares during the last quarter. GAMMA Investing LLC grew its position in shares of Praxis Precision Medicines by 6,075.4% during the 1st quarter. GAMMA Investing LLC now owns 4,014 shares of the company’s stock valued at $152,000 after buying an additional 3,949 shares during the last quarter. Aberdeen Group plc grew its position in shares of Praxis Precision Medicines by 143.5% during the 2nd quarter. Aberdeen Group plc now owns 214,056 shares of the company’s stock valued at $9,001,000 after buying an additional 126,153 shares during the last quarter. Assenagon Asset Management S.A. grew its position in shares of Praxis Precision Medicines by 19.1% during the 2nd quarter. Assenagon Asset Management S.A. now owns 604,298 shares of the company’s stock valued at $25,411,000 after buying an additional 96,898 shares during the last quarter. Finally, Cormorant Asset Management LP boosted its stake in Praxis Precision Medicines by 3.1% during the 1st quarter. Cormorant Asset Management LP now owns 1,745,000 shares of the company’s stock valued at $66,083,000 after purchasing an additional 51,781 shares during the period. Institutional investors own 67.84% of the company’s stock.

About Praxis Precision Medicines

Praxis Precision Medicines, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy.